Log In
Print this Print this

ocrelizumab (R1594, RG1594)

Also known as: Anti-CD20, Ocrevus

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionSecond-generation humanized mAb against CD20
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat primary progressive multiple sclerosis (PPMS); Treat relapsing multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation U.S. - Breakthrough Therapy (Treat primary progressive multiple sclerosis (PPMS));
U.S. - Priority Review (Treat primary progressive multiple sclerosis (PPMS))
PartnerGenentech Inc.;

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today